Valuation

NVSNovartis AG

StockNYSESwitzerlandHealth careEU retail investors: available

−0.3% today · +32.3% over a year

10/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 99% of the instruments we score

Quality, Stability: among the best of its peers; priced lower than most peers. Dividend yield 2.41%.

Novartis AG (NVS) valuation against sector peers: P/E 22.3 (sector median 25.7), P/B 6.8, EV/EBIT 18.7, free-cash-flow yield 5.6%.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricNVSSector medianvs median
P/E22.325.7 · n=2613% below
P/B6.83.6 · n=4585% above
P/S—4.7 · n=40—
EV/EBIT18.722.6 · n=2818% below
Free-cash-flow yield5.6%3.8% · n=3950% above
Dividend yield2.41%0.19% · n=991,152% above
Return on equity31.0%5.2% · n=56495% above
Return on invested capital25.0%6.5% · n=47286% above
Gross margin—70.2% · n=39—
Net debt / EBITDA—2.08 · n=25—

Value factor: 85 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

NOVNNovartis AG22.46.818.75.6%2.8%10/10
AZNAstraZeneca PLC28.35.922.84.1%1.2%5/10
AZNAstraZeneca plc28.35.922.84.1%1.7%6/10
NVONovo Nordisk A/S11.86.210.34.9%4.6%7/10
SNYSanofi13.41.518.26.9%4.3%7/10
SANSanofi SA13.41.518.26.9%4.8%9/10
GSKGSK plc14.55.111.87.7%3.5%9/10
TEVATeva Pharmaceutical Industries Limited97.86.243.32.5%0.0%6/10
ALCAlcon AG37.51.729.34.7%0.5%5/10
ALCAlcon36.81.628.84.8%0.4%4/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 31 Dec 2025 · filed 04 Feb 2026